Vanflyta Tablet, Film Coated
NDC Package 65597-511-28

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Other Packages
    3. Frequently Asked Questions

Package Information

Vanflyta (quizartinib) tablets is vANFLYTA is indicated in combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy, for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 internal tandem duplication (ITD)-positive as detected by an FDA-approved test [see Dosage and Administration (2.1) and Clinical Studies (14)]. This formulation utilizes a tablet, film coated delivery system. Marketed by Daiichi Sankyo Inc., this product is identified by NDC 65597-511 and is authorized under FDA application NDA216993.

Identification & Billing

NDC Package Code
65597-511-28
Package Description
1 BOTTLE in 1 CARTON / 28 TABLET, FILM COATED in 1 BOTTLE
Product Code
65597-511
11-Digit Billing Format
65597051128
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
Units Per Package
1 EA
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Vanflyta
Non-Proprietary Name
Quizartinib
Substance Name
Quizartinib Dihydrochloride
Dosage Form
Tablet, Film Coated - A solid dosage form that contains medicinal substances with or without suitable diluents and is coated with a thin layer of a water-insoluble or water-soluble polymer.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
QUIZARTINIB DIHYDROCHLORIDE 26.5 mg/1
Pharmacologic Class
Usage Information
VANFLYTA is indicated in combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy, for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 internal tandem duplication (ITD)-positive as detected by an FDA-approved test [see Dosage and Administration (2.1) and Clinical Studies (14)].

Regulatory & Marketing

Labeler Name
Daiichi Sankyo Inc.
Product Type
Human Prescription Drug
FDA Application #
NDA216993
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
07-20-2023
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (65597-511). Click a package code to view its specific billing and regulatory data.

65597-511-04
1 BOTTLE in 1 CARTON / 14 TABLET, FILM COATED in 1 BOTTLE

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 65597-511-28 identifies a specific commercial package of 1 bottle in 1 carton / 28 tablet, film coated in 1 bottle of Vanflyta, a human prescription drug labeled by Daiichi Sankyo Inc.. This product is billed for "EA" each discreet unit and contains an estimated amount of 1 billable units per package. This tablet, film coated is formulated for oral use and contains quizartinib dihydrochloride as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Daiichi Sankyo Inc. on July 20, 2023. The current certification is valid through December 31, 2027.

How is this Daiichi Sankyo Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 65597051128. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 1 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
65597-511-28
11-Digit CMS (5-4-2)
65597-0511-28

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.